Korean J Urol.  2007 Feb;48(2):199-205. 10.4111/kju.2007.48.2.199.

Study of the Duration of Pyuria after Transurethral Prostatectomy

• Cho KH
• Song KH
• Chang YS

• KMID: 2139761
• DOI: http://doi.org/10.4111/kju.2007.48.2.199

Abstract

PURPOSE: Persistent pyuria is one of the common complications after transurethral prostatectomy (TURP). Postoperative pyuria has an effect on postoperative voiding symptoms. Thus, postoperative urinalysis and urine culture are reliable indicators when following up voiding symptoms. In our study, possible preoperative, intraoperative and postoperative factors influencing the development and duration of pyuria and bacteriuria after TURP were evaluated.
MATERIALS AND METHODS
Between January 2004 and November 2005, 82 patients who underwent TURP due to benign prostatic hyperplasia (BPH) were evaluated. The risk factors of the duration of the postoperative pyuria were divided into preoperative, intraoperative postoperative, and evaluated the differences and correlations according to these risk factors.
RESULTS
The average durations of pyuria of 26 and 23 patients under and over the age of 70 were 4.12+/-2.69 and 6.61+/-4.51 weeks, respectively (p= 0.03). The average duration of pyuria of 12 patients with no preoperative pyuria and 37 with preoperative pyuria were 4.97+/-3.12 and 6.25+/-5.55 weeks, respectively (p=0.04). Separating patients according to the resected volume of prostate, the average duration of pyuria of 16 and 33 patients with resected prostate volumes greater than and less than 7g were 3.56+/-2.16 and 6.12+/-4.20 weeks, respectively (p=0.03). The age and average duration of pyuria showed a positive correlation (p=0.031). CONCLISIONS: Significant differences were observed in the duration of pyuria according to age, preoperative pyuria and resected volume of prostate.

Keyword

Transurethral prostatectomy; Pyuria

MeSH Terms

Bacteriuria
Humans
Prostate
Prostatic Hyperplasia
Pyuria*
Risk Factors
Transurethral Resection of Prostate*
Urinalysis

Figure

• 

  Fig. 1 Correlation curve between the duration of pyuria and voiding symptoms.

Reference

1. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003. 61:267–273.

2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984. 132:474–479.

3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003. 170:530–547.

4. John MF, Winston KM. Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Minimally invasive and endoscopic management of benign prostatic hyperplasia. Campbell's urology. 2002. 8th ed. Philadelphia: Saunders;1379–1422.

5. Lim KB, Wong MY, Foo KT. Transurethral resection of prostate (TURP) through the decades - a comparison of results over the last thirty years in a single institution in Asia. Ann Acad Med. 2004. 33:775–779.

6. Knopf HJ, Weib P, Schafer W, Funke PJ. Nosocomial infections after transurethral prostatectomy. Eur Urol. 1999. 36:207–212.

7. Glenn SG, Charles BB. Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Evaluation of the urologic patient: history, physical examination, and urinalysis. Campbell's urology. 2002. 8th ed. Philadelphia: Saunders;83–110.

8. Gibbons RP, Stark RA, Correa RJ Jr, Cummings KB, Mason JT. The prophylactic use- or misuse- of antibiotics in transurethral prostatectomy. J Urol. 1978. 119:381–383.

9. Roehrborn CG, McConnell JD. Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Campbell's urology. 2002. 8th ed. Philadelphia: Saunders;1297–1330.

10. Schatzl G, Madersbacher S, Djavan B, Lang T, Marberger M. Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options. Eur Urol. 2000. 37:695–701.

11. McAllister WJ, Absalom MJ, Mir K, Shivde S, Anson K, Kirby RS, et al. Does endoscopic laser ablation of the prostate stand the test of time? Five-year results from a multicentre randomized controlled trial of endoscopic laser ablation against transurethral resection of the prostate. BJU Int. 2000. 85:437–439.

12. Keoghane SR, Lawrence KC, Gray AM, Doll HA, Hancock AM, Turner K, et al. A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int. 2000. 85:74–78.

13. Lee SD, Shin JH. Clinical observation for complications of transurethral resection in the treatment of benign prostatic hyperplasia. Korean J Urol. 1990. 31:429–435.

14. Na TK, Kim DK, Yoo TK. Transurethral prostatectomy for the patients over 80 years old: is it really safe? Korean J Urol. 2000. 41:1086–1090.

15. Kim TS, Choi S, Rhew HY, Ahn JH, Jang JH, Cho MH. Comparative study on the treatment outcome and safety of TURP, ILC, TUNA and TEAP for patients with benign prostatic hyperplasia. Korean J Urol. 2006. 47:13–19.

16. Kim TJ, Suh JK, Kim YS, Park TC. Complications of transurethral prostatectomy. Korean J Urol. 1992. 33:679–684.

17. Okamura K, Takaba H, Ito K, Shimoji T. The course of pyuria after transurethral resection of the prostate and factor analysis of its duration. Hinyokika Kiyo. 1987. 33:889–893.

18. Fujita K, Matsushima H, Munakata A, Kunitake T. Multifactorial analysis of the pyuria after transurethral prostatectomy. Nippon Hinyokika Gakkai Zasshi. 1992. 83:1999–2004.

19. Oka T, Takano Y, Miyagawa Y, Satoh E, Tei N, Seko M, et al. Study on the duration of pyuria after transurethral resection of prostate. Hinyokika Kiyo. 1998. 44:391–396.

20. Holtgrewe HL, Valk WL. Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2,015 cases. J Urol. 1962. 87:450–459.

21. Melchior J, Valk WL, Foret JD, Mebust WK. Transurethral prostatectomy: computerized analysis of 2,223 consecutive cases. J Urol. 1974. 112:634–642.

22. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989. 141:243–247.

23. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician. 2005. 71:1153–1162.

24. Smith RB. Smith RB, Ehrlich RM, editors. Complications of transurethral surgery. Complications of urologic surgery: prevention and management. 1990. 2nd ed. Philadelphia: Saunders;355–376.

25. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol. 2006. 50:969–980.

26. Liu GG, Nguyen T, Nichol MB. An economic analysis of antimicrobial prophylaxis against urinary tract infection in patients undergoing transurethral resection of the prostate. Clin Ther. 1999. 21:1589–1604.

27. Nam JG, Choi NG. Evaluation of persistent lower urinary tract symptoms after transurethral resection of prostate. Korean J Urol. 2003. 44:540–544.

28. Jeon HJ, Chung HC, Song JM. Effects of residual prostatic calculi on lower urinary tract symptoms after transurethral resection of prostate. Korean J Urol. 2005. 46:569–573.